Following Connecticut Governor Ned Lamont’s budget address to members of the General Assembly, BioCT’s President and CEO, Dawn Hocevar, issued the following statement.
Imposing arbitrary mandates on biopharmaceutical innovation, especially in the midst of the worst public health crisis Connecticut and the country have seen in a lifetime, can dry up investment into early stage companies who are innovators in the development of health solutions, and potentially risk lives.
The Connecticut bioscience industry has again shown its critical importance this year, and as we emerge from this pandemic, stifling research and development—which this proposal will do—puts the public and the lives of patients, living with some of the most complex diseases, at risk, not to mention our preparedness for the next
pandemic.